Genentech's Vabysmo Shows Real-World Efficacy Across Major Retinal…

Event summary

Genentech presented new real-world data from the VOYAGER study at EURETINA 2026, confirming Vabysmo's effectiveness and safety across wet AMD, DME, and RVO.
After 12 months, Vabysmo treatment showed vision gains and anatomical improvements in untreated eyes and stable or improved vision with anatomical outcomes in previously treated eyes.
The study involved over 5,000 patients across 28 countries/regions and utilized AI and deep learning algorithms for SD-OCT image evaluation.

The big picture

Genentech's Vabysmo is positioning itself as a cornerstone therapy for major retinal conditions, with real-world data reinforcing its role in addressing unmet needs. The study's global scale and AI-driven analysis underscore the drug's potential to reshape treatment paradigms in ophthalmology. As the biotech sector increasingly focuses on real-world evidence, Vabysmo's sustained visual gains and safety profile could drive further market penetration and differentiation.

What we're watching

Market Adoption: How the real-world data will accelerate Vabysmo's adoption in diverse global practices, particularly for patients with complex treatment histories.
Treatment Durability: Whether the observed extension of treatment intervals with fewer injections will enhance patient compliance and reduce healthcare costs.
Competitive Positioning: The pace at which Genentech can leverage these results to solidify Vabysmo's market leadership against existing and emerging retinal therapies.